TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35903445

Group type: EXPERIMENTAL
Intervention: Serum serine levels (Q2, Q3, Q4)
Number of subjects: 20702

Group type: COMPARATOR
Intervention: Control group (Q1)
Number of subjects: 20702
Study: 35903448

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (2.4 g/day) plus venlafaxine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo plus venlafaxine
Number of subjects: 72
Study: 35903458

Group type: EXPERIMENTAL
Intervention: Severe underweight (weight-for-age z-scores [WAZ] < -3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox regression for anthropometric indicators
Number of subjects: 0
Study: 35903636

Group type: EXPERIMENTAL
Intervention: Intensive re-nutrition
Number of subjects: 36
Study: 35903678

Group type: EXPERIMENTAL
Intervention: Heat shock protein peptide complex 96 (HSPPC-96) vaccination
Number of subjects: 0
Study: 35904231

Group type: EXPERIMENTAL
Intervention: Non-myeloablative selective HSCT
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Myeloablative selective HSCT
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Non-myeloablative non-selective HSCT
Number of subjects: 226

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 226
Study: 35904632

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 35904671

Group type: EXPERIMENTAL
Intervention: Comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes, and biosampling.
Number of subjects: 5298
Study: 35904708

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab (0.5 mg/0.05 ml) before vitrectomy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravitreal injection of ranibizumab (0.5 mg/0.05 ml) at the end of vitrectomy
Number of subjects: 52
Study: 35904722

Group type: EXPERIMENTAL
Intervention: Lusutrombopag at 3 mg for up to 7 days
Number of subjects: 35
Study: 35904853

Group type: EXPERIMENTAL
Intervention: High-resolution features derived from wearable data
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Heart rate dynamics in sedentary states
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Heart rate dynamics in active states
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Higher resolution patterns in wearable heart rate recordings
Number of subjects: 692
Study: 35904867

Group type: EXPERIMENTAL
Intervention: Rehabkompassen (intervention group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual outpatient visits (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rehabkompassen at 12-month follow-up
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale (primary outcome)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Various stroke impacts (secondary outcomes)
Number of subjects: 28
Study: 35904878

Group type: EXPERIMENTAL
Intervention: You Cope, We Support (YCWS) - self-management relaxation exercises
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group - self-monitoring of outcomes and alerts or reminders
Number of subjects: 170
Study: 35904987

Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted vaccine containing 120 μg of RSVPreF3
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Unadjuvanted vaccine
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1053
Study: 35905198

Group type: EXPERIMENTAL
Intervention: ARISCAT risk index
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ASA III
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High ARISCAT grades
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Albumin < 35g/L
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age, male gender, duration of surgery, duration of OLV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preoperative albumin levels
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postoperative average visual analogue scale (VAS) score for pain at the 24th-hour
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Length of stay in the postoperative intensive care unit
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chest tube removal time
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Discharge time
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morbidity and mortality on the 90th-day
Number of subjects: 120
Study: 35905224

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia with remifentanil followed by propofol administration
Number of subjects: 50
Study: 35905229

Group type: EXPERIMENTAL
Intervention: Donor Fecal Microbiota Transplantation (FMT)
Number of subjects: 34
Study: 35905294

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 134
Study: 35905428

Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 854
Study: 35905860

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Microbial signature at T1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: PD index at T1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dorea sp. abundance at T1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: KEGG pathways at T1
Number of subjects: 41
Study: 35906349

Group type: EXPERIMENTAL
Intervention: Milvexian 60 mg single oral dose
Number of subjects: 8
Study: 35906574

Group type: EXPERIMENTAL
Intervention: Enhanced adherence counseling (EAC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Facility-based, individual EAC counseling
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Participant-suggested improvements to EAC
Number of subjects: 136
Study: 35906589

Group type: EXPERIMENTAL
Intervention: CONNECT intervention (modified for Quality)
Number of subjects: 0
Study: 35906602

Group type: EXPERIMENTAL
Intervention: Multiple data collection methods (interviews, observations, facilitator sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple data collection methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analytic methods (co-occurrence table, k-means clustering, taxonomic analysis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptation types
Number of subjects: 0
Study: 35906608

Group type: EXPERIMENTAL
Intervention: Natural history of Type 1 SMA (no specific intervention mentioned)
Number of subjects: 60
Study: 35906656

Group type: EXPERIMENTAL
Intervention: In-situ simulation training
Number of subjects: 71
Study: 35906676

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMI model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined cohorts from POPLAR and OAK trials
Number of subjects: 0
Study: 35906699

Group type: EXPERIMENTAL
Intervention: 12-week complementary and alternative medicine (CAM) program delivered by a therapist at a clinic; 20-session program consisting of yoga, Pilates, and dual tasking exercises.
Number of subjects: 837

Group type: COMPARATOR
Intervention: 12-week complementary and alternative medicine (CAM) program initiated by the participant at home using a tablet and pre-recorded videos; 20-session program consisting of yoga, Pilates, and dual tasking exercises.
Number of subjects: 837
Study: 35906831

Group type: EXPERIMENTAL
Intervention: Caspofungin (empiric therapy)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Preemptive antifungal strategy (arm B)
Number of subjects: 549
Study: 35906881

Group type: EXPERIMENTAL
Intervention: Anti-spike neutralizing monoclonal antibodies (nMoAbs)
Number of subjects: 91
Study: 35907107

Group type: EXPERIMENTAL
Intervention: LBBAP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOT-CRT
Number of subjects: 20
Study: 35907135

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day; 0.75 mg/day for moderate renal impairment)
Number of subjects: 19
Study: 35907408

Group type: EXPERIMENTAL
Intervention: Haploidentical bone marrow transplantation
Number of subjects: 32
Study: 35907430

Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG low dose (5×10^10 viral particles), n=3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG middle dose (5×10^10 viral particles), n=3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG high dose (5×10^10 viral particles), n=6
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year for middle-dose or high-dose recipients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Administration of a licensed rabies vaccine after ChAdOx2 RabG
Number of subjects: 12
Study: 35907438

Group type: EXPERIMENTAL
Intervention: DAPT duration <6 months (n=273)
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: DAPT duration 6 to 12 months (n=477)
Number of subjects: 1827

Group type: COMPARATOR
Intervention: DAPT duration 12 to 24 months (n=637)
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: DAPT duration ≥ 24 months (n=440)
Number of subjects: 1827
Study: 35907755

Group type: EXPERIMENTAL
Intervention: Ultra-low temperature cryoablation (ULTC)
Number of subjects: 78
Study: 35907978

Group type: EXPERIMENTAL
Intervention: Biologics therapy (Etanercept, Abatacept, Tocilizumab)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Methotrexate (concomitant treatment)
Number of subjects: 480
Study: 35908067

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS) for 6 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Three-day bladder diary
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PPIUS
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ICIQ-OAB
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: KHQ
Number of subjects: 23
Study: 35908120

Group type: EXPERIMENTAL
Intervention: Patient guide 'Are Mammograms Still Right for Me?'
Number of subjects: 45
Study: 35908242

Group type: EXPERIMENTAL
Intervention: Inotersen (inotersen-inotersen)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo to Inotersen (placebo-inotersen)
Number of subjects: 109
Study: 35908658

Group type: EXPERIMENTAL
Intervention: Novel press-fit Percutaneous Osseointegrated Prosthesis (POP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Socket suspension system
Number of subjects: 10
Study: 35908569

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily for 10 days
Number of subjects: 8156

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 8156

Group type: EXPERIMENTAL
Intervention: JAK inhibitors (including baricitinib) in meta-analysis
Number of subjects: 8156

Group type: EXPERIMENTAL
Intervention: Baricitinib or another JAK inhibitor in updated meta-analysis
Number of subjects: 8156
Study: 35909174

Group type: EXPERIMENTAL
Intervention: Increased PEEP by 50% above baseline
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Increased PEEP
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Capnodynamic monitoring
Number of subjects: 27
Study: 35909213

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/day
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Lamotrigine (post hoc analysis)
Number of subjects: 264
Study: 35909254

Group type: EXPERIMENTAL
Intervention: Benzodiazepines during the first trimester
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Psychiatric medications other than benzodiazepines
Number of subjects: 1053
Study: 35909297

Group type: EXPERIMENTAL
Intervention: Predictive model for gestational diabetes based on maternal demographics and clinical parameters.
Number of subjects: 3263
Study: 35909569

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 392

Group type: COMPARATOR
Intervention: Lenvatinib
Number of subjects: 392
Study: 35910354

Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific intervention details not available
Number of subjects: 0
Study: 35910889

Group type: EXPERIMENTAL
Intervention: Maternal metabolic indicators (insulin, glucose, insulin growth factor 1, hemoglobin A1c) at early pregnancy (<15 and 26-28 weeks of gestation)
Number of subjects: 1954

Group type: EXPERIMENTAL
Intervention: Maternal dietary intake and mental health problems derived from the COVID-19 pandemic
Number of subjects: 1954
Study: 35911528

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed warfarin therapy (PMWT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 59
Study: 35911547

Group type: EXPERIMENTAL
Intervention: Multimodal approach combining clinical, imaging, biological and electrocardiographic markers
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Multimodal approach
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Galectin-3 ≧ 9 ng/ml
Number of subjects: 240
Study: 35911663

Group type: EXPERIMENTAL
Intervention: Atherectomy and DCB (Drug-Coated Balloon)
Number of subjects: 2895

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 2895
Study: 35911702

Group type: EXPERIMENTAL
Intervention: Induction immunochemotherapy (iIC) with PD-1 inhibitor plus chemotherapy every 3 weeks for at least two cycles
Number of subjects: 155

Group type: COMPARATOR
Intervention: Induction chemotherapy (iC)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Conversion surgery following immunochemotherapy
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAE)
Number of subjects: 155
Study: 35911824

Group type: EXPERIMENTAL
Intervention: Stoss therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard of care vitamin D supplementation
Number of subjects: 41
Study: 35911899

Group type: EXPERIMENTAL
Intervention: Prolong Life with Nine Turn method (PLWNT) Qigong
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 34
Study: 35912221

Group type: EXPERIMENTAL
Intervention: Nanosecond pulsed electric field (nsPEF)
Number of subjects: 192
Study: 35912650

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control (older patients, matched cohort)
Number of subjects: 363
Study: 35912709

Group type: EXPERIMENTAL
Intervention: Methamphetamine use
Number of subjects: 66299

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 66299

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 66299

Group type: COMPARATOR
Intervention: Alcohol abuse
Number of subjects: 66299

Group type: COMPARATOR
Intervention: Cocaine use
Number of subjects: 66299
Study: 35913400

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab
Number of subjects: 0
Study: 35913436

Group type: EXPERIMENTAL
Intervention: Very high coffee and/or tea consumption (≥4 cups/day)
Number of subjects: 3788

Group type: EXPERIMENTAL
Intervention: High coffee and/or tea consumption (3 cups/day)
Number of subjects: 3788

Group type: EXPERIMENTAL
Intervention: Moderate coffee and/or tea consumption (2 cups/day)
Number of subjects: 3788

Group type: COMPARATOR
Intervention: Low coffee and/or tea consumption (<1 cup/day)
Number of subjects: 3788
Study: 35913563

Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 18
Study: 35913656

Group type: EXPERIMENTAL
Intervention: Predictive Low-Glucose Suspend (PLGS) duration > 157.5 min/day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: PLGS duration ≤ 174.4 min/day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mean daily PLGS duration between 157.5 and 174.4 min/day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Basal insulin percentage < 52.0%
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Total Daily Dose (TDD) adaptation
Number of subjects: 110
Study: 35913657

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) analysis measured prior to the induction of anaesthesia and immediately before eyeball traction.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Initial ANS tone assessment based on frequency domain HRV parameters from 5-min Holter electrocardiogram recordings.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Initial heart rate, blood pressure, age, sex, and ASA status.
Number of subjects: 52
Study: 35913883

Group type: EXPERIMENTAL
Intervention: Therapeutic immediacy events initiated by therapists
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Good outcome cases
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Poor outcome cases
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Frequency and rated quality of immediacy events
Number of subjects: 4
Study: 35914096

Group type: EXPERIMENTAL
Intervention: Base-in prism (n = 22)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vision therapy/exercises (n = 35)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 57
Study: 35914222

Group type: EXPERIMENTAL
Intervention: Reduced-dose apixaban (2.5 mg twice daily)
Number of subjects: 732

Group type: COMPARATOR
Intervention: No anticoagulation (D-dimer negative patients)
Number of subjects: 732
Study: 35914226

Group type: EXPERIMENTAL
Intervention: CD19-CARCD7- T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bulk CD19-CAR T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD19-CARCD7lo T cells
Number of subjects: 0
Study: 35914227

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant with gene therapy (ASCT-GT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 35914239

Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide (A/C) followed by paclitaxel for neoadjuvant systemic therapy (NAST)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Biologically based model using MRI data
Number of subjects: 56

Group type: COMPARATOR
Intervention: Tumor volume measured after four cycles of A/C
Number of subjects: 56
Study: 35914538

Group type: EXPERIMENTAL
Intervention: ReStoreD: Promoting Resilience after Stroke in Dyads (8-week self-administered dyadic positive psychology intervention)
Number of subjects: 26
Study: 35914576

Group type: EXPERIMENTAL
Intervention: IFAB-Turkish version (IFAB-Tr)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 93
Study: 35914905

Group type: EXPERIMENTAL
Intervention: Indocyanine green clearance test (IGT) administered to the donor, with a cut-off value of 13% for plasma disappearance rate (PDR).
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Indocyanine green clearance test (IGT) measured at different time-points in the LT recipient: during the anhepatic phase, after graft reperfusion, at 24 hours, on day 3 and day 7 after LT.
Number of subjects: 162
Study: 35915019

Group type: EXPERIMENTAL
Intervention: PCSK9 levels measured at baseline and after 5 days (ng/ml)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Rate of apoptosis (AR) of human umbilical vein endothelial cells incubated with patients' serum
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Reduction of PCSK9 in patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 5-day change of PCSK9
Number of subjects: 74
Study: 35915020

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 17259

Group type: COMPARATOR
Intervention: No Radiotherapy (Control)
Number of subjects: 17259

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Number of subjects: 17259

Group type: EXPERIMENTAL
Intervention: Black Race
Number of subjects: 17259

Group type: EXPERIMENTAL
Intervention: Private Insurance
Number of subjects: 17259

Group type: EXPERIMENTAL
Intervention: Age ≥ 70 years
Number of subjects: 17259

Group type: EXPERIMENTAL
Intervention: Tumor size > 20 mm
Number of subjects: 17259

Group type: EXPERIMENTAL
Intervention: CDCC score > 0
Number of subjects: 17259
Study: 35915157

Group type: EXPERIMENTAL
Intervention: Panitumumab (anti-EGFR monoclonal antibody)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard third-line treatments
Number of subjects: 52
Study: 35915181

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 78
Study: 35915419

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET) initiation by 12-month interview
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET) continuation for ≥12 months by 24-month interview
Number of subjects: 533

Group type: COMPARATOR
Intervention: Diabetes status
Number of subjects: 533

Group type: COMPARATOR
Intervention: Menopausal-symptom severity
Number of subjects: 533
Study: 35915479

Group type: EXPERIMENTAL
Intervention: Residence-Based Testing Participation Pilot (RB-TPP)
Number of subjects: 464
Study: 35602670

Group type: EXPERIMENTAL
Intervention: Oligometastatic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polymetastatic treatment
Number of subjects: 0
Study: 35915738

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual therapy with fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual therapy with umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 0
Study: 35915749

Group type: EXPERIMENTAL
Intervention: GuttaFlow2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GuttaCore
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold lateral compaction (CLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold free-flow compaction (GuttaFlow2)
Number of subjects: 0
Study: 35916001

Group type: EXPERIMENTAL
Intervention: Tele-assessment of core strength and endurance tests (Curl-up, Modified Push-up, Plank, Lateral Bridge)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tele-assessment of functional capacity tests (Timed Up and Go, 30 second Sit to Stand, Functional Reach Test)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tele-assessment method
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tele-assessment of core strength-endurance and functional tests
Number of subjects: 80
Study: 35916675

Group type: EXPERIMENTAL
Intervention: Dispersion slope (DS) measurements from 2D shear-wave elastography (SWE)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Liver stiffness (LS) measurements from 2D shear-wave elastography (SWE)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combination of DS and LS measurements from 2D shear-wave elastography (SWE)
Number of subjects: 159